INVA | Innoviva, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	18.83 - 19.58
52 Week Range	12.22 - 19.85
Beta	0.58
Implied Volatility	36.95%
IV Rank	25.80%
Day's Volume	656,024
Average Volume	515,187
Shares Outstanding	62,562,500
Market Cap	1,193,066,875
Sector	Healthcare
Industry	Biotechnology
IPO Date	2004-10-05

Valuation
Profitability
Growth
Health
P/E Ratio	10.77
Forward P/E Ratio	N/A
EPS	1.77
1YR Price Target	17.75
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	112
Country	USA
Website	INVA

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

INVA's peers: GTX, EFTR, PLX, PDSB, LIFE, ELEV, DAWN, MRTX, AMLX, TERN, APLS, XFOR, INZY, HOOK, ABOS, FOLD, INCY, DNLI, ARGX, HRMY

*Chart delayed

Analyzing fundamentals for INVA we got that it has strong fundamentals where Valuation is considered to be significantly undervalued, Profitability is stunning wealthy, Growth is very good and Health is very strong. For more detailed analysis please see INVA Fundamentals page.

Watching at INVA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on INVA Technicals page.